Publications by authors named "M O Nour"

This systematic review provides a comprehensive comparison of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors in the management of chronic heart failure (CHF), with a focus on their long-term efficacy and safety profiles. By synthesizing evidence from randomized controlled trials (RCTs) and clinical studies, the review highlights the significant benefits of both drug classes in reducing mortality and hospital readmissions, and improving patient outcomes. Beta-blockers, such as bisoprolol and carvedilol, demonstrated superior efficacy in reducing sudden cardiac death, particularly in patients with heart failure with reduced ejection fraction (HFrEF).

View Article and Find Full Text PDF

Rationale: Working memory impairment is a prominent feature of schizophrenia which predicts clinical and functional outcomes. Preclinical data suggest histamine-3 receptor (H3R) expression in cortical pyramidal neurons may have a role in working memory, and post-mortem data has found disruptions of H3R expression in schizophrenia.

Objectives: We examined the role of H3R in vivo to elucidate its role on working memory impairment in schizophrenia.

View Article and Find Full Text PDF

Pharmacological interventions are a cornerstone of psychiatric practice. The taxonomies used to classify these interventions influence the treatment and interpretation of psychiatric symptoms. Disease-based classification systems (e.

View Article and Find Full Text PDF
Article Synopsis
  • This study assesses the cost-effectiveness of mobile stroke units (MSUs) compared to standard emergency medical services (EMS) for administering thrombolytics in ischemic stroke patients.
  • The analysis used the incremental cost-effectiveness ratio (ICER) method to evaluate healthcare costs and quality-adjusted life years (QALYs), highlighting considerable variations based on patient disability status and treatment costs.
  • Overall, while MSUs show borderline cost-effectiveness for all eligible patients, they are more favorable for patients without pre-existing disabilities, particularly when focusing on lifetime costs and stroke-specific expenses.
View Article and Find Full Text PDF